Conn. Gen. Stat. § 17a-484g
Psychedelic-assisted therapy pilot program
Connecticut · General Statutes of Connecticut Chapter 319i — Persons with Psychiatric Disabilities · Status: effective
Cite this
- Citation
- Conn. Gen. Stat. § 17a-484g, Psychedelic-assisted therapy pilot program, Connecticut, version 1 as recorded 2026-10-03, yourstate.us, https://yourstate.us/provision/2182929
- Permanent ID
ys:prov:2182929@1- SHA-256
2e9fa16e01b0146117ccf1dfc33b633329a94c0c902a50029c3dac6dbb8f5f15
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) As used in this section:
(1) “MDMA” means the synthetic psychoactive drug, 3,4-methylenedioxymethamphetamine, commonly known as ecstasy or molly, that acts as a serotonin receptor agonist and reuptake inhibitor of serotonin and dopamine.
(2) “Psilocybin” means a serotonin receptor agonist that occurs naturally in some mushroom species.
(3) “Qualified patient” means a resident of the state who is (A) a veteran, (B) a retired first responder, or (C) a direct care health care worker.
(b) Not later than January 1, 2023, the Department of Mental Health and Addiction Services shall establish, within available appropriations, a psychedelic-assisted therapy pilot program, to be administered by a medical school in the state. Such pilot program shall provide qualified patients with MDMA-assisted or psilocybin-assisted therapy as part of a research program approved by the federal Food and Drug Administration pursuant to 21 CFR 312, as amended from time to time. The department shall cease to operate the pilot program when MDMA and psilocybin have been approved to have a medical use by the Drug Enforcement Administration, or any successor agency.